Swiss National Bank Has $604,000 Stake in Lion Biotechnologies Inc. (LBIO)
Swiss National Bank maintained its stake in shares of Lion Biotechnologies Inc. (NASDAQ:LBIO) during the second quarter, Holdings Channel reports. The firm owned 74,600 shares of the biotechnology company’s stock at the end of the second quarter. Swiss National Bank owned 0.15% of Lion Biotechnologies worth $604,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. Quantitative Investment Management LLC acquired a new stake in shares of Lion Biotechnologies during the second quarter worth approximately $117,000. Bank of New York Mellon Corp raised its stake in shares of Lion Biotechnologies by 2.8% in the second quarter. Bank of New York Mellon Corp now owns 183,631 shares of the biotechnology company’s stock worth $1,488,000 after buying an additional 5,001 shares during the period. Quantitative Systematic Strategies LLC acquired a new stake in shares of Lion Biotechnologies during the second quarter worth approximately $178,000. Finally, Bank of Montreal Can acquired a new stake in shares of Lion Biotechnologies during the second quarter worth approximately $151,000. Institutional investors and hedge funds own 75.54% of the company’s stock.
Lion Biotechnologies Inc. (NASDAQ:LBIO) traded up 1.119% during mid-day trading on Thursday, hitting $6.775. 127,596 shares of the stock traded hands. The firm’s 50-day moving average is $8.03 and its 200 day moving average is $7.31. The firm’s market cap is $395.90 million. Lion Biotechnologies Inc. has a 52-week low of $4.24 and a 52-week high of $9.58.
Lion Biotechnologies (NASDAQ:LBIO) last issued its earnings results on Monday, August 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.04. Equities analysts predict that Lion Biotechnologies Inc. will post ($0.88) EPS for the current fiscal year.
A number of brokerages have commented on LBIO. Zacks Investment Research lowered shares of Lion Biotechnologies from a “hold” rating to a “sell” rating in a research note on Tuesday, September 6th. Roth Capital restated a “buy” rating and set a $15.00 price target on shares of Lion Biotechnologies in a research note on Friday, August 26th. Finally, Chardan Capital set a $20.00 price target on shares of Lion Biotechnologies and gave the company a “buy” rating in a research note on Sunday, August 21st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $19.17.
In related news, Director Sanford Hillsberg sold 54,000 shares of the firm’s stock in a transaction on Thursday, August 25th. The stock was sold at an average price of $8.95, for a total value of $483,300.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 11.80% of the stock is owned by corporate insiders.
Lion Biotechnologies Company Profile
Lion Biotechnologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma.
Want to see what other hedge funds are holding LBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lion Biotechnologies Inc. (NASDAQ:LBIO).
Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.